These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 38440893)
21. Update of clinical application in ceftazidime-avibactam for multidrug-resistant Gram-negative bacteria infections. Zhen S; Wang H; Feng S Infection; 2022 Dec; 50(6):1409-1423. PubMed ID: 35781869 [TBL] [Abstract][Full Text] [Related]
22. Tannic Acid-Stabilized Silver Nanoparticles Used in Biomedical Application as an Effective Antimelioidosis and Prolonged Efflux Pump Inhibitor against Melioidosis Causative Pathogen. Srichaiyapol O; Thammawithan S; Siritongsuk P; Nasompag S; Daduang S; Klaynongsruang S; Kulchat S; Patramanon R Molecules; 2021 Feb; 26(4):. PubMed ID: 33672903 [No Abstract] [Full Text] [Related]
23. In vitro activity of ceftazidime-avibactam against gram-negative bacteria in patients with bacteremia and skin and soft-tissue infections in Colombia 2019-2021. Lemos-Luengas EV; Rentería-Valoyes S; Muñoz DMA; Gonzalez CKG; Guerrón-Gómez G; Ramos-Castaneda JA Diagn Microbiol Infect Dis; 2024 Jun; 109(2):116235. PubMed ID: 38458096 [TBL] [Abstract][Full Text] [Related]
24. Characterization of synergy between ofloxacin, ceftazidime, and tobramycin against Pseudomonas aeruginosa. Madaras-Kelly KJ; Moody J; Larsson A; Baeker Hovde L; Rotschafer JC Chemotherapy; 1997; 43(2):108-17. PubMed ID: 9084919 [TBL] [Abstract][Full Text] [Related]
25. In vitro synergistic activities of tobramycin and selected beta-lactams against 75 gram-negative clinical isolates. Owens RC; Banevicius MA; Nicolau DP; Nightingale CH; Quintiliani R Antimicrob Agents Chemother; 1997 Nov; 41(11):2586-8. PubMed ID: 9371376 [TBL] [Abstract][Full Text] [Related]
26. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae? Marshall S; Hujer AM; Rojas LJ; Papp-Wallace KM; Humphries RM; Spellberg B; Hujer KM; Marshall EK; Rudin SD; Perez F; Wilson BM; Wasserman RB; Chikowski L; Paterson DL; Vila AJ; van Duin D; Kreiswirth BN; Chambers HF; Fowler VG; Jacobs MR; Pulse ME; Weiss WJ; Bonomo RA Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167541 [TBL] [Abstract][Full Text] [Related]
27. Silver nanoparticles as a bioadjuvant of antibiotics against biofilm-mediated infections with methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa in chronic rhinosinusitis patients. Feizi S; Cooksley CM; Nepal R; Psaltis AJ; Wormald PJ; Vreugde S Pathology; 2022 Jun; 54(4):453-459. PubMed ID: 34844745 [TBL] [Abstract][Full Text] [Related]
28. Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro. Lin Q; Zou H; Chen X; Wu M; Ma D; Yu H; Niu S; Huang S BMC Microbiol; 2021 Feb; 21(1):60. PubMed ID: 33618662 [TBL] [Abstract][Full Text] [Related]
29. Antibacterial and biofilm-inhibitory effects of vancomycin-loaded mesoporous silica nanoparticles on methicillin-resistant staphylococcus aureus and gram-negative bacteria. Memar MY; Yekani M; Farajnia S; Ghadiri Moghaddam F; Nabizadeh E; Sharifi S; Maleki Dizaj S Arch Microbiol; 2023 Mar; 205(4):109. PubMed ID: 36884153 [TBL] [Abstract][Full Text] [Related]
30. Fabrication and antimicrobial properties of novel meropenem-honey encapsulated chitosan nanoparticles against multiresistant and biofilm-forming Staphylococcus aureus as a new antimicrobial agent. Hajimohammadi S; Momtaz H; Tajbakhsh E Vet Med Sci; 2024 May; 10(3):e1440. PubMed ID: 38613443 [TBL] [Abstract][Full Text] [Related]
31. Biofilm prevention of gram-negative bacterial pathogens involved in periprosthetic infection by antibiotic-loaded calcium sulfate beads in vitro. Howlin RP; Winnard C; Frapwell CJ; Webb JS; Cooper JJ; Aiken SS; Stoodley P Biomed Mater; 2016 Dec; 12(1):015002. PubMed ID: 27910828 [TBL] [Abstract][Full Text] [Related]
32. [In vitro activity of ceftazidime-avibactam combined with colistin against extensively drug-resistant Pseudomonas aeruginosa]. Mei Q; Geng S; Fang X; He Y; Liu L; Xu M; Zhu C; Pan A Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2019 Oct; 31(10):1212-1218. PubMed ID: 31771717 [TBL] [Abstract][Full Text] [Related]
33. Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model. den Hollander JG; Horrevorts AM; van Goor ML; Verbrugh HA; Mouton JW Antimicrob Agents Chemother; 1997 Jan; 41(1):95-100. PubMed ID: 8980762 [TBL] [Abstract][Full Text] [Related]
34. Pharmacodynamics of ceftazidime plus tobramycin combination dosage regimens against hypermutable Pseudomonas aeruginosa isolates at simulated epithelial lining fluid concentrations in a dynamic in vitro infection model. Tait JR; Bilal H; Kim TH; Oh A; Peleg AY; Boyce JD; Oliver A; Bergen PJ; Nation RL; Landersdorfer CB J Glob Antimicrob Resist; 2021 Sep; 26():55-63. PubMed ID: 34023531 [TBL] [Abstract][Full Text] [Related]
35. Insights into the preparation of zein nanoparticles by continuous membrane nanoprecipitation. Condello A; Piacentini E; Giorno L Int J Biol Macromol; 2024 Apr; 265(Pt 1):130935. PubMed ID: 38493815 [TBL] [Abstract][Full Text] [Related]
36. Synergistic effect and antibiofilm activity of the antimicrobial peptide K11 with conventional antibiotics against multidrug-resistant and extensively drug-resistant Chatupheeraphat C; Peamchai J; Luk-In S; Eiamphungporn W Front Cell Infect Microbiol; 2023; 13():1153868. PubMed ID: 37113135 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of the efficacy and safety of ceftazidime/avibactam in the treatment of Gram-negative bacterial infections: a systematic review and meta-analysis. Zhong H; Zhao XY; Zhang ZL; Gu ZC; Zhang C; Gao Y; Cui M Int J Antimicrob Agents; 2018 Oct; 52(4):443-450. PubMed ID: 30012440 [TBL] [Abstract][Full Text] [Related]
38. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199 [TBL] [Abstract][Full Text] [Related]
39. Systematic Evaluation of the Accelerate Pheno System for Susceptibility Testing of Gram-Negative Bacteria Isolated from Blood Cultures. Patel YA; Kirn TJ; Weinstein MP; Uprety P Microbiol Spectr; 2021 Dec; 9(3):e0183621. PubMed ID: 34937177 [TBL] [Abstract][Full Text] [Related]
40. Efficacy and mortality of ceftazidime/avibactam-based regimens in carbapenem-resistant Gram-negative bacteria infections: A retrospective multicenter observational study. Zhuang HH; Chen Y; Hu Q; Long WM; Wu XL; Wang Q; Xu TT; Qu Q; Liu YP; Xiao YW; Qu J J Infect Public Health; 2023 Jun; 16(6):938-947. PubMed ID: 37087853 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]